2026-06-01T08:50:54Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88072024-03-13T01:05:28Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Valldeoriola Serra, Francesc 7054d7d3-0de8-465c-b976-07177a4b36f6 600 Catalán, María José 53b4ab97-7734-4839-a7b4-4bdba6d8b766 600 Escamilla-Sevilla, Francisco 6aa10739-9e5f-4f09-8c31-bc72c42553cc 600 Freire, Eric 5e2631aa-d575-4ad4-a802-215c63df3742 600 Olivares Romero, Jesús 7f6aab0c-e4e9-4dcc-9dea-4d536122c226 600 Cubo Delgado, Esther 131 600 0000-0003-0018-1182 Calopa, Matilde ee4f8b31-e4e5-405e-918f-5ee88321dfbc 600 Martínez Martín, Pablo 3b256da2-afa7-4d7d-91e0-61436565bbac 600 Parra, Juan Carlos 02896ff1-9e8a-46ea-acca-bdd549d48f47 600 Arroyo, Gloria f14d7764-efdf-4b18-a472-256a604842d5 600 Arbelo, José Matías 6e563f58-2458-49c8-b707-0151a0fd3513 600 2024-03-12T11:50:27Z 2024-03-12T11:50:27Z 2021-11 http://hdl.handle.net/10259/8807 10.1038/s41531-021-00246-y 2373-8057 Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, −12.8 ± 14.6; P < 0.0001), motor symptoms (UPDRS-III in “On,” −6.5 ± 11.8; P = 0.0002), NMS (NMSS, −35.7 ± 31.1; P < 0.0001), mood (Norris/Bond-Lader VAS, −6.6 ± 21.1; P = 0.0297), fatigue (PFS-16, −0.6 ± 1.0; P = 0.0003), depression (BDI-II, −5.1 ± 9.4; P = 0.0002), anxiety (BAI, −6.2 ± 9.6; P < 0.0001), and patient treatment satisfaction (SATMED-Q, 16.1 ± 16.8; P < 0.0001). There were significant correlations between the change from baseline to 6 months between PDQ-39 and UPDRS-IV, NMSS, BAI, BDI-II, AS, and PFS-16 scores, and Norris/Bond-Lader alertness/sedation factor. Caregiver anxiety also improved (Goldberg anxiety scale, −1.1 ± 1.0; P = 0.0234), but the clinical relevance of this finding is questionable. The serious adverse events reported were similar to those previously described for LCIG. In patients with APD, LCIG improves QoL, motor symptoms and NMS, emotional well-being, and satisfaction with the treatment. Improvement in patient QoL is associated with improvements in motor complications, NMS, anxiety, depression, apathy and fatigue. Improvements in patients’ QoL does not correspond with improvements in caregivers’ QoL or burden. application/pdf eng Springer Nature npj Parkinson's Disease. 2021, V. 7, n. 1 https://doi.org/10.1038/s41531-021-00246-y Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion npj Parkinson's Disease 7 1 THUMBNAIL Valldeoriola-npjpd_2021.pdf.jpg Valldeoriola-npjpd_2021.pdf.jpg IM Thumbnail image/jpeg 3720 https://riubu.ubu.es/bitstream/10259/8807/4/Valldeoriola-npjpd_2021.pdf.jpg 0ed28253e7ad78a4351a1ef4e43f56ca MD5 4 LICENSE license.txt license.txt text/plain; charset=utf-8 999 https://riubu.ubu.es/bitstream/10259/8807/3/license.txt b295bcbce42e2caabeb0c623d3860c06 MD5 3 CC-LICENSE license_rdf license_rdf application/rdf+xml; charset=utf-8 908 https://riubu.ubu.es/bitstream/10259/8807/2/license_rdf 0175ea4a2d4caec4bbcc37e300941108 MD5 2 ORIGINAL Valldeoriola-npjpd_2021.pdf Valldeoriola-npjpd_2021.pdf application/pdf 1222118 https://riubu.ubu.es/bitstream/10259/8807/1/Valldeoriola-npjpd_2021.pdf 13e7c32979703a34dc805bce1c32caf7 MD5 1 10259/8807 oai:riubu.ubu.es:10259/8807 2024-03-13 02:05:28.944 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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